Español
Questions About Cancer? 1-800-4-CANCER
  • Print
  • Facebook
  • Twitter
  • Google+
  • Pinterest

NCI Drug Dictionary

  

VEGFR/PDGFR dual kinase inhibitor TAK-593 
An oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity. TAK-593 selectively binds to and inhibits VEGFR and PDGFR, which may result in the inhibition of angiogenesis and tumor cell proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Code name:TAK-593